RSU grant and exercise for YD Bio (YDES) director Chang Kochi

Rhea-AI Filing Summary

YD Bio Ltd director Chang Kochi reported equity compensation activity involving Restricted Share Units (RSUs) and ordinary shares. On June 30, 2026, Kochi exercised 5,749 RSUs into the same number of ordinary shares at a stated price of $0.0000 per share, increasing direct holdings to 7,830 ordinary shares.

On the same date, Kochi also received a new grant of 5,749 RSUs with each RSU representing one ordinary share of YD Bio Ltd. According to the equity plan, the RSUs relate to a target aggregate grant date fair value of $60,000, vesting in four equal quarterly installments determined using a seven trading-day volume-weighted average price.

Insider Trade Summary

5,749 shares exercised/converted

Mixed 3 txns

Insider Chang Kochi

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	5,749	$0.00	--
Exercise	Restricted Share Units	5,749	$0.00	--
Exercise	Ordinary Shares	5,749	$0.00	--

Holdings After Transaction: Restricted Share Units — 5,749 shares (Direct, null); Ordinary Shares — 7,830 shares (Direct, null)

Footnotes (1)

1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting. The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

Key Figures

RSUs exercised: 5,749 RSUs / 5,749 shares Ordinary shares held: 7,830 shares New RSU grant size: 5,749 RSUs +3 more

6 metrics

RSUs exercised 5,749 RSUs / 5,749 shares Exercise into ordinary shares on June 30, 2026

Ordinary shares held 7,830 shares Direct holdings after June 30, 2026 transactions

New RSU grant size 5,749 RSUs Grant reported with transaction code A on June 30, 2026

Target grant value $60,000 Aggregate target grant date fair value on March 31, 2026

Quarterly vesting tranche $15,000 per tranche Each of four quarterly installments under equity plan

VWAP basis 7 trading days Volume‑weighted average price period for RSU share calculation

Key Terms

Restricted Share Units, Equity Incentive Plan, volume-weighted average price

3 terms

Restricted Share Units financial

"The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Equity Incentive Plan financial

"The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

volume-weighted average price financial

"by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 03:33 PM Accepted by SEC EDGAR 07/01/2026 - 03:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chang Kochi

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI CITY 115001

(City) (State) (Zip)

TAIWAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/30/2026		M		5,749	A	(1)	7,830	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	06/30/2026		A		5,749(2)(3)		(2)	(2)	Ordinary Shares	5,749	$0	5,749	D
Restricted Share Units	(1)	06/30/2026		M			5,749	(2)	(2)	Ordinary Shares	5,749	$0	0	D

Explanation of Responses:

1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

3. The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

	/s/ Kochi Chang	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did YD Bio (YDES) director Chang Kochi report?

Chang Kochi exercised 5,749 Restricted Share Units into 5,749 ordinary shares and received a new grant of 5,749 RSUs. These transactions are equity compensation events, not open‑market share purchases or sales.

How many YD Bio ordinary shares does Chang Kochi hold after these Form 4 transactions?

After the reported transactions, Chang Kochi directly holds 7,830 ordinary shares of YD Bio Ltd. This reflects the conversion of 5,749 RSUs into ordinary shares on June 30, 2026, as disclosed in the Form 4.

What are the terms of Chang Kochi’s new RSU grant at YD Bio (YDES)?

The new RSUs have an aggregate target grant date fair value of $60,000, granted on March 31, 2026. They vest in four equal quarterly installments, each calculated by dividing $15,000 by a seven trading‑day volume‑weighted average price of YD Bio’s ordinary shares.

Does the YD Bio Form 4 show any open‑market buying or selling by Chang Kochi?

The Form 4 does not show open‑market buying or selling. All reported transactions are coded as derivative exercises (M) and a grant (A), reflecting equity compensation activity rather than discretionary market trades in YD Bio’s ordinary shares.

What does each YD Bio RSU reported for Chang Kochi represent?

Each Restricted Share Unit represents a contingent right to receive one ordinary share of YD Bio Ltd. Delivery of shares depends on vesting conditions specified in the equity incentive plan and reaching the applicable vesting dates described in the Form 4 footnotes.